Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
Audrey Abella, 6 days ago
The use of angiotensin converting enzyme (ACE) inhibitors may prevent repeat revascularization in patients who underwent percutaneous transluminal angioplasty (PTA) for peripheral artery disease (PAD) compared with angiotensin receptor blockers (ARB), according to a presentation at APCH 2017.

ADT ups risks of heart failure, arrhythmia in localized prostate cancer patients

Jairia Dela Cruz
16 Sep 2017

Androgen deprivation therapy (ADT) carries an increased risk of certain cardiovascular disease (CVD) outcomes, namely heart failure, arrhythmia and conduction disorder, in men with localized prostate cancer, a recent study suggests.

Findings from a cohort of localized prostate cancer patients who initially underwent active surveillance indicated that ADT was associated with a greater risk of heart failure, especially among those without CVD history (adjusted hazard ratio [HR], 1.81; 95 percent CI, 1.40 to 2.32). [Br J Cancer 2017;doi:10.1038/bjc.2017.280]

Exposure to the hormone treatment also increased the risks of arrhythmia (adjusted HR, 1.44; 1.02 to 2.01) and conduction disorder (adjusted HR, 3.11; 1.22 to 7.91) but only among patients with pre-existing CVD.

“The observed increased risk of arrhythmia among ADT users in our study is consistent with the confirmed inverse association between testosterone level and prolonged QT interval, a strong risk factor for fatal arrhythmias,” the investigators said. [Am J Epidemiol 2011;174:412–415]

They also noted the possibility that prostate cancer patients with pre-existing CVD may be more susceptible to developing conduction disorders or that such patients are more likely to have greater healthcare utilization, be monitored frequently and, hence, more likely to be diagnosed with other CVD conditions.

A total of 7,637 patients comprised the study population, with nearly 30 percent (n=2,170) exposed to ADT during a median follow-up of 3.4 years. Of the patients, 78 percent (n=5,972) had no prior CVD history.  

CVD events occurred in 2,061 patients over 31,255 person-years, with an incidence rate of 65.9 events per 1,000 person-years. Average time to a CVD event was 3.2 years.

Given that heart failure, arrhythmia and conduction disorder affect patients’ quality of life and morbidity, possibly compromising survival, the current study is said to provide the basis for identifying susceptible individuals for regular cardiac check-up.

“The implication is that patients with localized prostate cancer should be followed to minimize the health effects of androgen deprivation therapy on the cardiovascular system," said lead investigator, Dr Reina Haque from the Kaiser Permanente Southern California Department of Research & Evaluation.

Patients should consider and discuss the positive and negative effects of ADT with their physicians, Haque continued. “If they move forward with the therapy, patients should work with their physicians to adjust their lifestyle to reduce the risk of cardiovascular disease.”

Despite having a large population, a long-term follow-up and the ability to adjust for a comprehensive set of covariates, the study might be limited by residual confounding for indication with the possibility that some factors that might influence ADT use and its outcomes were not captured. Furthermore, only one subtype of ADT (ie, GnRH agonists) was examined and without distinguishing between intermittent and continuous ADT administration.

“Future observational studies need to examine CVD outcomes in prostate cancer survivors who have been diagnosed in more recent years when the newer GnRH antagonist drugs were launched into the market and follow them for sufficient time to compare the long-term safety of different subtypes of ADT,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
Audrey Abella, 6 days ago
The use of angiotensin converting enzyme (ACE) inhibitors may prevent repeat revascularization in patients who underwent percutaneous transluminal angioplasty (PTA) for peripheral artery disease (PAD) compared with angiotensin receptor blockers (ARB), according to a presentation at APCH 2017.